21 March 2023
Comparing in silico and in vitro methods for classification of BCS II and CYP3A4 and MDR-1 substrate specificity
Fagerholm. BioRxiv December 15, 2022.https://www.biorxiv.org/content/10.1101/2022.12.13.520246v1
21 November 2022
Evaluation of the reliability and applicability of human unbound brain-to-plasma concentration ratios
Fagerholm. BioRxiv November 21, 2022.https://www.biorxiv.org/content/10.1101/2022.11.14.516429v1
14 November 2022
Validation of predicted conformal intervals for prediction of human clinical pharmacokinetics
Fagerholm, Alvarsson, Hellberg, Spjuth. BioRxiv November 14, 2022. https://www.biorxiv.org/content/10.1101/2022.11.10.515917v1
14 November 2022
New article and ANDROMEDA milestone- Successful validation
Validation of predicted conformal intervals for prediction of human clinical pharmacokinetics https://www.biorxiv.org/content/10.1101/2022.11.10.515917v1
10 October 2022
ANDROMEDA by Prosilico software successfully predicts human clinical pharmacokinetics of 70 drugs out of reach for in vitro methods
Fagerholm, Hellberg, Alvarsson, Spjuth. BioRxiv October 7, 2022. https://www.biorxiv.org/content/10.1101/2022.10.05.511015v1
3 October 2022
Steps in the right direction!
FDA Modernization Act - The bill defines “nonclinical tests or studies ” as a test…
3 October 2022
An analysis of laboratory variability and thresholds for human in vitro ADME/PK methods
Fagerholm. BioRxiv September 28, 2022. https://www.biorxiv.org/content/10.1101/2022.09.27.509731v1
